Oncology

Of 55 evaluable patients in ZUMA-3, 71% achieved complete remission (CR) or CR with incomplete hematological recovery (CRi).

The director of myeloma immunotherapy at University of Pennsylvania discussed cilta-cel's efficacy in lenalidomide-refractory multiple myeloma.

Review top news and interview highlights from the week ending September 2, 2022.

The company has filed a patent for the new approach, which is designed to combat T-cell exhaustion.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A pre-treatment TME with high levels of cytokines and chemokines was associated with complete response to axi-cel treatment.

In an ovarian cancer mouse model, the combination therapy group showed an 83% increase in survival duration compared to an untreated group.

The company has initiated the world’s first confirmatory phase 2 trial of a CAR T-cell therapy in solid tumors.

Michael Heffernan, chairman and chief executive officer, Avenge Bio, discussed the IND clearance of AVB-001 and the soon-to-initiate phase 1 trial.

The tumor-infiltrating lymphocyte therapy has shown efficacy in the phase 2 C-144-01 trial.

Review top news and interview highlights from the week ending August 26, 2022.

The senior vice president and head of medical affairs at Orca Bio discussed how Orca-T has been developed to lower the risk of graft-versus-host disease.

Century Therapeutics will initiate the phase 1 ELiPSE-1 study imminently.

The senior vice president of immunology at Cellectis discussed the company’s investigational dual-targeted CAR-T therapy for B-cell malignancies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A case study showed that the patient achieved a complete response in 12 months after treatment with CARsgen Therapeutics’ cell therapy.

At a median follow-up of 24 months, the best ORR achieved was 77.6% among 58 evaluable patients with large B-cell lymphoma treated with relma-cel.

Thirty-five patients were previously treated with Innovative Cellular Therapeutics’ GCC19CART in an IRB-approved trial in China.

If approved, the company will initiate the first-in-human STAR-101 phase 1 clinical trial.

Review top news and interview highlights from the week ending August 19, 2022.

The company recently announced a dose escalation in the ACCLAIM-1 study.

Higher doses were associated with improved overall survival, event-free survival, and relapse-free survival.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Tessa Therapeutics presented positive data from the phase 2 CHARIOT study of TT11 in December 2021.

Multiple cell and gene therapy companies have been granted patents for novel technology in 2022.